59 related articles for article (PubMed ID: 9378968)
1. The novel C24D synthetic polypeptide inhibits binding of placenta immunosuppressive ferritin to human T cells and elicits anti-breast cancer immunity in vitro and in vivo.
Solodeev I; Zahalka MA; Moroz C
Neoplasia; 2014 Sep; 16(9):741-50. PubMed ID: 25246274
[TBL] [Abstract][Full Text] [Related]
2. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.
Simon-Keller K; Paschen A; Hombach AA; Ströbel P; Coindre JM; Eichmüller SB; Vincent A; Gattenlöhner S; Hoppe F; Leuschner I; Stegmaier S; Koscielniak E; Leverkus M; Altieri DC; Abken H; Marx A
Am J Pathol; 2013 Jun; 182(6):2121-31. PubMed ID: 23562272
[TBL] [Abstract][Full Text] [Related]
3. Reduction of CTLL-2 cytotoxicity by induction of apoptosis with a Fas-estrogen receptor chimera.
Kametaka M; Kume A; Okada T; Mizukami H; Hanazono Y; Ozawa K
Cancer Sci; 2003 Jul; 94(7):639-43. PubMed ID: 12841875
[TBL] [Abstract][Full Text] [Related]
4. TNF superfamily: costimulation and clinical applications.
Vinay DS; Kwon BS
Cell Biol Int; 2009 Apr; 33(4):453-65. PubMed ID: 19230849
[TBL] [Abstract][Full Text] [Related]
5. Distinct gene signature revealed in white blood cells, CD4(+) and CD8(+) T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide.
Singh RP; Dinesh R; Elashoff D; de Vos S; Rooney RJ; Patel D; La Cava A; Hahn BH
Genes Immun; 2010 Jun; 11(4):294-309. PubMed ID: 20200542
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.
Tita-Nwa F; Moldenhauer G; Herbst M; Kleist C; Ho AD; Kornacker M
Cancer Immunol Immunother; 2007 Dec; 56(12):1911-20. PubMed ID: 17487487
[TBL] [Abstract][Full Text] [Related]
7. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Huang J; Kerstann KW; Ahmadzadeh M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunol; 2006 Jun; 176(12):7726-35. PubMed ID: 16751420
[TBL] [Abstract][Full Text] [Related]
8. Crystallization and preliminary X-ray crystallographic study of the extracellular domain of the 4-1BB ligand, a member of the TNF family.
Byun JS; Kim DU; Ahn B; Kwon BS; Cho HS
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Jan; 62(Pt 1):23-5. PubMed ID: 16511253
[TBL] [Abstract][Full Text] [Related]
9. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
Xu T; Sun BC; Li Q; Hao XS
World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
[TBL] [Abstract][Full Text] [Related]
10. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer.
Tsukishiro T; Donnenberg AD; Whiteside TL
Cancer Immunol Immunother; 2003 Oct; 52(10):599-607. PubMed ID: 12827303
[TBL] [Abstract][Full Text] [Related]
11. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.
Chopin D; Barei-Moniri R; Maillé P; Le Frère-Belda MA; Muscatelli-Groux B; Merendino N; Lecerf L; Stoppacciaro A; Velotti F
Am J Pathol; 2003 Apr; 162(4):1139-49. PubMed ID: 12651606
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand and the fate of antitumour cytotoxic T lymphocytes.
O'Connell J
Immunology; 2002 Mar; 105(3):263-6. PubMed ID: 11918687
[No Abstract] [Full Text] [Related]
13. The regulation of FasL expression during activation-induced cell death (AICD).
Nguyen T; Russell J
Immunology; 2001 Aug; 103(4):426-34. PubMed ID: 11529932
[TBL] [Abstract][Full Text] [Related]
14. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.
Hellstrom I; Ledbetter JA; Scholler N; Yang Y; Ye Z; Goodman G; Pullman J; Hayden-Ledbetter M; Hellstrom KE
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6783-8. PubMed ID: 11371607
[TBL] [Abstract][Full Text] [Related]
15. Prospects for vaccination in prostate cancer.
Perry MJ; Hroulda D; Dalgleish AG
Drugs Aging; 2000 May; 16(5):321-7. PubMed ID: 10917069
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.
Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT
Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418
[TBL] [Abstract][Full Text] [Related]
17. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.
Daniel PT; Kroidl A; Cayeux S; Bargou R; Blankenstein T; Dörken B
J Immunol; 1997 Oct; 159(8):3808-15. PubMed ID: 9378968
[TBL] [Abstract][Full Text] [Related]
18. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death.
Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL
Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322
[TBL] [Abstract][Full Text] [Related]
19. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
